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A variety of animal models have been developed for modeling ischemic stroke. The middle cerebral artery occlusion (MCAO)
model has been utilized extensively, especially in rodents. While the MCAO model provides stroke researchers with an excellent
platform to investigate the disease, controversial or even paradoxical results are occasionally seen in the literature utilizing this
model. Various factors exert important eﬀects on the outcome in this stroke model, including the age and sex of the animal
examined. This paper discusses emerging information on the eﬀects of age and sex on ischemic outcomes after MCAO, with an
emphasis on mouse models of stroke.
1.Introduction
Stroke is the third major cause of mortality and the
leading cause of long-term disability in the United States.
Ischemic stroke accounts for approximately 80% of all
strokes [1]; however, only one FDA- approved therapy exists
for treatment of acute ischemic stroke, the thrombolytic
tissueplasminogenactivator(tPA)[2].Inordertoinvestigate
the mechanisms underlying injury after ischemic stroke as
well as to develop eﬀective therapeutic approaches to the
disease, several ischemic stroke models have been developed
in a variety of species, including rodents, canines, rabbits,
c a t s ,a n de v e nn o n h u m a np r i m a t e s[ 3–6]. Models of stroke
that can be used in rodents are becoming increasingly
popular at bench because (1) genetically-engineered mice
are particularly useful for furthering our understanding of
components of ischemic pathophysiology and in designing
potential new preventative, neuroprotective, and therapeutic
drugs and interventions; (2) a number of neurosensory
and motor behavior outcomes have become standardized
for rodents, which facilitates the assessment of functional
outcomes after experimental stroke [7]; (3) the public tends
to have fewer animal welfare concerns regarding rodents in
research compared to nonrodents [7–10]. In general, there
are four major types of animal models of ischemic stroke:
(1) complete global cerebral ischemia; (2) incomplete global
ischemia; (3) focal cerebral ischemia and (4) Multifocal
cerebral ischemia [10] (Figure 1). Since ischemic stroke
in patients usually results from a thrombotic or embolic
occlusion in a major cerebral artery, most often the middle
cerebral artery (MCA), experimental focal cerebral ischemia
models have been developed to mimic human stroke and
serveasanindispensabletoolinthestrokeresearchﬁeld[11].
However, all experimental models of disease have weak-
nesses and stroke modeling is no exception, especially
with the reliance on rodent models. Despite many promis-
ing pharmacological agents that dramatically reduce tissue
injury after experimental stroke at the bench, none have
been translated to eﬃcacious agents for clinical use. Possible
reasons for this “lack of translation” have been recently
reviewed elsewhere [12, 13], but some of the most obvious
but frequently ignored factors will be discussed here, that
is, the eﬀect of age and sex on stroke outcomes. Most
experimental stroke studies have been done exclusively in
young male animals, although stroke is a disease that mainly
aﬀects the elderly [14]. Stroke is also sexually dimorphic2 Journal of Biomedicine and Biotechnology
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Figure 1: Major types of animal models of ischemic stroke.
in clinical populations with diﬀerent functional outcomes,
age of onset, and etiologies in men and women [15].
We will describe the most commonly used models in the
investigation of stroke in rodents, with a focus on the MCAO
model, and discuss some of the limitations of this model as it
is currently used. Several common factors that can inﬂuence
histological and behavioral outcomes including aging and
sex/hormonal factors will also be discussed.
2.ModelingStroke: MCAO Model
Four major rodent models of focal cerebral ischemia
have been developed: (1) models not requiring cran-
iotomy (embolic model, intraluminal suture MCAO model,
photothrombosis model, and endothelin-1-induced stroke
model), (2) models requiring craniotomy (Tamura’s model),
(3) posterior cerebral circulation stroke models, and (4)
cerebral venous thrombosis models. These have been the
subject of an excellent comprehensive review [11]a n dw i l l
not be discussed here except for the intraluminal model.
Among these well-developed models, MCAO is widely used
and has been extended to the mouse in recent genetic
studies of cell death mechanisms. This model oﬀers a
simpler and less traumatic surgical approach compared with
craniotomy models, lends itself more readily to the study
of reperfusion and has been adapted for use in continuous
magnetic resonance imaging [16], produces focal occlusion
of a large cerebral artery as seen in human stroke, and can be
done in a high-throughput manner [17]. Rigorous control
of temperature, physiological variables, and assessment of
occlusion with noninvasive means (i.e., Laser Doppler)
reduces variability.
2.1. Infarct Size Induced by MCAO. The reversible MCAO
model has been well studied and utilized by stroke
researchers due to its clinically relevant nature that mimics
recanalization of an embolized or thrombosed vessel by tPA
(Figure 2). Although the model has been employed to study
ischemic stroke for decades, the evolution of infarct within
theareabloodsuppliedbyMCAhasnotbeenwellelucidated.
Therefore signiﬁcant controversy exists due to the variability
of ﬁnal infarct size and debate as to the most reliable
time point to measure the eﬀects of various therapeutic
agents [9, 18, 19]. Generally speaking, infarct development
appears to be more rapid in mice than in rats as well as
in reperfusion versus permanent “nonreperfusion” MCAO
models. Previous studies have demonstrated an increase
in infarct volumes even as late as 3d after stroke in rats
[20, 21]; however these animals had no restoration of blood
ﬂow which may delay infarct development. In a previous
study [16] we have shown that 90-minute occlusion of the
MCA induces a peak volume of injury as delineated by
TTC staining by 24h in mice which remains unchanged
through day 7 of reperfusion (Figure 3). We also observed
a spatiotemporal evolution of core and penumbra: at earlier
time points (2 and 6 hours after occlusion), the histological
infarct core, as measured by TTC, is limited to the striatum,
and the viable tissue surrounded this core and included
much of the cortex. Subsequently the “TTC-deﬁned” core
expands to involve most of the cortical tissue supplied by
the MCA. This occurs quite rapidly and is complete (by
TTC) within 6–12 hours after stroke onset. It is unclear if
any intervention begun several hours after ischemic onset
can reduce recruitment of the penumbra. Certainly by 12
hours, all of the territory supplied by the MCA is irreversibly
damaged. Studies with MRI in rat models of transientJournal of Biomedicine and Biotechnology 3
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Figure 2: Diagram of cerebrovascular anatomy and MCAO in rats. Reprinted with permission from Longa, EZ et al., Stroke 1989 20: 84–91.
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Figure 3: Evolution of infarct in mouse brain after 90-minute MCAO.
MCAO [22, 23] demonstrated that stroke-induced infarct
evolved into an area of injury of similar magnitude to
the initial diﬀusion disturbance by 24h as measured by a
reduced apparent diﬀusion coeﬃcient and prolonged T2
signals. Several previous studies have also revealed that
apoptosis induced by transient MCAO model reached its
peak at 24–48h of stroke [24, 25]. In murine reperfusion
models, increases in T2 signal were seen extremely early (by
90 minutes) in the infarct area, indicative of edema and
breakdown of the blood-brain barrier, which were not seen
after permanent occlusion. This suggests that reperfusion
mayaccelerateinfarctdevelopment,atleastinmice[26].The
dynamics of the penumbra are also diﬀerent between strains,
as measured by MRI [27]. The spontaneously hypertensive
rat and its stroke-prone cohort develop larger and much less
variable infarcts following MCAO [28]. The rapid evolution
of the penumbra does emphasize one of the limitations
in clinical neuroprotection studies. Most animal studies
have administered a putative neuroprotective agent either
pre-ischemia, intraischemia, or very soon after reperfusion
[29–31], time windows that are impossible to mimic in
clinical trials. Although a prolonged “therapeutic window”
does allow for a greater number of patients to be treated,
it is unlikely that salvageable tissue is present, especially
after successful reperfusion if it occurs after 8 hours.
Attempting to treat patients without radiographic evidence
o fp e n u m b r a lt i s s u ea f t e r6h o u r si sl i k e l ya ne x e r c i s e
in futility and dilutes any potential beneﬁt of an acute4 Journal of Biomedicine and Biotechnology
neuroprotective agent. Other mechanisms that predominate
after injury, such as inﬂammation, may be more viable
targets [32].
Interestingly, diﬀerent histological staining methods
reveal diﬀerent evolving patterns of infarct tissue or degen-
erating neurons. Each method has advantages and disadvan-
tages. For example, while TTC staining of MCAO-induced
brain injury demonstrated no further enlargement of infarct
after 24h of stroke, Fluoro-Jade B [33] staining showed
neuronal degeneration peaked at 24h, increased by 48 hours
but decreased to baseline values by 7d after stroke [16].
This suggests that Fluoro-Jade B is a more sensitive marker
for acute neuronal degeneration but may not be as useful
for assessment of chronic damage, which is more accurately
performed with cresyl violet (CV). TTC is a marker of
tissue dehydrogenase and mitochondrial dysfunction and
may not represent irreversible cell death, therefore it may
overestimate infarct size [34]. Longer-term assessment of
infarct also suggests that damage, as measured by acute
TTC staining, overestimates the degree of injury. 50% of the
ischemic hemisphere is poorly stained by TTC acutely, but
at 30 days, only 10–20% of the hemispheric volume is lost
(unpublished observations). This suggests that TTC may not
reliably reﬂect tissue death, but rather tissue dysfunction.
Fluoro-JadeBisveryspeciﬁcforneuronaldeathbutbecomes
inaccurate after several days, as the degenerating neurons
have often been removed, leading to an underestimate of
neuronalinjury.CVisgoodforlong-termstudiesbutistime-
consuming. A combination of methods is likely the most
accurate, and both short-(24–72hrs) and long-term (weeks)
histological outcomes should be assessed prior to clinical
development of any neuroprotective agent.
2.2. Modeling Stroke Risk Factors. Increased stroke risk
factorsaremajorcontributingfactorstotherisingprevalence
of stroke and include hypertension, obesity, and diabetes
[35]. Models for these important risk factors have been
developed. For example, the APO E-deﬁcient (apoE−/−)
mouse, established in 1992, is of the most important animal
models of atherosclerosis [36]. Spontaneously hypertensive
(SH) rats are utilized as a “stroke-prone” animal model
and widely used in hypertension studies [37]. Mutation of
cystathionine β-synthetase (CBS), which induces enhanced
atherothrombosis [38], has also been investigated. Although
modeling stroke risk factors has advanced our knowledge of
these disorders, the interaction with age and sex has been
frequently ignored.
3. Effect of Age on Modeling MCAO
Aging is the most important independent risk factor for
stroke. Older patients have higher in-hospital mortality as
well as poorer functional outcomes after an ischemic event
[14]. Although age is one of the most signiﬁcant prognostic
markers for poor outcome [39], very few studies have been
performed in aged animals, especially in animals over 15
months of age. Numerous neurochemical and physiological
changes occur with aging [40]. Aging animals have less
edema formation after stroke compared to the young
[41], and NKCC, a Na-K-Cl cotransporter, is expressed
at a lower level in aging mice than in young mice after
MCAO [42], suggesting a possible mechanism for this
ﬁnding. Clinical postmortem studies [43] also conﬁrmed
more robust edema formation in the young brain after
stroke and is in part the rationale for proposing an upper
age limit of 60 for hemicraniectomy [44]. Recent data
suggests that ischemic preconditioning is less eﬀective in the
aged heart in both experimental and clinical studies [45],
and our study also found that Compound C, adenosine
monophosphate-activated protein kinase (AMPK) inhibitor
which has been proved to be neuroprotective in young
animals after MCAO [46, 47], has no eﬀect in aging animals
(manuscript submitted). The continued clinical failure of
promising neuroprotective agents [48] has led us to question
the appropriateness of modeling stroke in young animals.
New paradigms for conducting translational research in
aging animals are urgently needed.
It is far more diﬃcult to perform MCAO in aging
rodents. Aging animals are usually heavier with higher
amounts of visceral fat, are less tolerant to anesthesia,
and have less ﬂexible vessels making insertion of occluding
sutures much more diﬃcult than in young animals. Aging
animals have higher mortality after MCAO due to frailty,
peripheral immunesupression, and other comorbid diseases
[41]. Stroke researchers frequently avoid using aging animals
for MCAO due to the more complex surgical procedure
and high cost of purchasing and raising animals. Very
few experimental studies exist in the literature that have
examined middle aged and aging animals, and these have
led to somewhat inconsistent results. Kharlamov et al. [49]
found no diﬀerence in infarct size at 24 hours when male
Fisherratsofthreediﬀerentagegroups(4,20,and27months
old) were evaluated. In another study, age was associated
with an increase in infarct size from 9 to 12% in the
neocortex and striatum in aged male Wistar rats [50]. In
contrast,otherstudieshavesuggestedthathistologicalinfarct
damage may be paradoxically higher in young (3 months)
compared to old (24–26 months) male rats [51]. Many of
the studies that have shown an age-related increase in stroke
volume used female animals (as they are smaller than age-
matched males), and ﬁndings may also be related to the
loss of ovarian hormones with aging [52]. Our previous
studies have deﬁnitively shown that aging male mice have
signiﬁcantly smaller infarcts than young males after 24h of
90-minute MCAO [41], at least at the histological level. This
diﬀerence can be detected even as long as 30d after MCAO
(unpublished data). In spite of the disagreements between
the histological eﬀects of aging on infarct volume (with
some showing larger and others showing smaller infarct
injury), invariably signiﬁcantly higher mortality rates and
more severe neurological impairments are found in the older
animals. For example, one study that examined 3-4 month
versus 22–24-month-old male rats demonstrated a mortality
rate of 43.5% in aged rats compared to 9% in the young [53].
Despite the fact that the mortality risk from the ischemic
damage is greater for old mice, we have found that eventual
recovery (4 weeks after stroke) is not diﬀerent from that ofJournal of Biomedicine and Biotechnology 5
a young mouse in most simple behavioral tests, although the
“slope”ofrecoveryismuchslower.Anexceptionisthecorner
test (manuscript submitted). The correlation between brain
damage, behavioral recovery, and age needs to be further
investigated.
Given that young and aging animals are usually of diﬀer-
ent weights at the time of MCAO, it is not surprising that the
cerebral vessels are also of diﬀerent size and dimension. To
ensure adequate and equivalent levels of cerebral blood ﬂow
(CBF) reduction, we have utilized diﬀerent sizes of occluding
sutures in young and aging mice. We have found that in
[41, 42]y o u n gm i c e( 2 0∼ 25mg), successful occlusion
requires a 0.21mm suture, but in aging mice (30 ∼ 40mg),
a larger 0.23mm suture is required to obtain the same
degree of CBF reduction. Our experience emphasizes the
importance of routine laser Doppler blood ﬂow monitoring
to ensure adequate (85% drop from prestroke baseline) in
murine MCAO models. This not only reduces variability
but also ensures that each animal experiences the same level
of cerebral ischemia, as this can have dramatic eﬀects on
outcomes. Several other issues need to be considered when
utilizing aging animals in research, including the higher rates
of infections and malignancy.
4. Effect of Sex on Modeling MCAO
It is increasingly recognized that the epidemiology of
ischemic stroke is sexually dimorphic [15], and therapeutic
agents aimed at stroke function diﬀerently in male and
female subjects. For example, anticoagulated women had a
relative risk of 2.0 for ischemic stroke versus anticoagulated
men [54], suggesting sex diﬀerences in coagulation. Women
experience a greater beneﬁt from tissue plasminogen acti-
vator (tPA) treatment than men [55]. Clinical trials of the
21-aminosteroid lipid peroxidation inhibitor tirilazad con-
ducted in traumatic brain injury, subarachnoid hemorrhage,
ischemic stroke, and spinal cord injury indicated that the
beneﬁcial eﬀect of tirilazad was greater in males than females
[56, 57]. These sex diﬀerences are becoming increasingly
apparent in clinical populations. The vast majority of
preclinical studies also continue to exclusively use male
animals. There are signiﬁcant limitations to this approach, as
we discuss here, utilizing estrogen (E2) as an example. Prior
to menopause, women have a lower risk of stroke relative
to age-matched men [58]. After menopause, the incidence
of stroke in women increases [59], coincident with the
diminished circulating levels of estrogen and progesterone
and surpasses that of men. Therefore, this pattern of stroke
risk has been attributed to the presence of protective female
sex hormones. Over the past thirty years, the majority of
cohort, retrospective, or prospective observational studies
have demonstrated signiﬁcant reductions in cardiovascular
disease in postmenopausal women receiving E2 (ERT) or
combined estrogen-progestin therapy (HRT) [60]. A grow-
ing number of preclinical studies have also documented
sexual dimorphism in stroke. Female rats and mice of many
diﬀerent inbred and outbred strains sustain smaller tissue
damage for an equivalent insult from focal or global cerebral
ischemia [61]. The “female-protected” phenotype can often
bereversedbyinducingsurgicalmenopauseviaovariectomy,
and protection can be recapitulated in male animals by
administration of exogenous estrogens [62]. E2 has neu-
rotrophic, antiapoptotic, vasodilatory, anti-inﬂammatory,
and antioxidant eﬀects, each of which could contribute
to improved outcome in the brains of males and females
[63]. E2 treatment at physiological relevant concentrations
reduces infarction after MCAO in ovariectomized (OVX) or
reproductively senescent female animals [64, 65], as well as
in males [61, 66], even when given after MCAO [62].
TheWoman’sHealthInitiative(WHI),thelargestclinical
trial of E2 replacement for stroke prevention, showed a
surprising increase in stroke incidence in estrogen-treated
woman [67, 68]. The explanation for these ﬁndings has been
debated extensively in the literature [67] but is thought to be
due to the unexpected proinﬂammatory eﬀects of estrogen
administration after a long period of “hypoestrogenemia”.
A recent study in mice demonstrated that prolonged loss
of E2 prior to replacement (10 weeks) ameliorated the
neuroprotective and anti-inﬂammatory eﬀects of E2 seen
in MCAO-model [69]. It appears that timing of estrogen
replacement after the menopause is critical to outcome in
both animal models and clinical trials. Women involved in
theWHItrialwereconsiderablyolder(averageageof63)and
well past menopause (which occurs at an average age of 51)
prior to randomization [70, 71]. In the Northern Manhattan
Stroke Study, stroke rates in women do not equalize to
those of men until beyond 75 years of age suggesting that
considerable time passes before females lose the protection
of gonadal steroids.
In addition to the timing of E2 replacement, other factors
may also aﬀect the eﬀects of E2 in MCAO induced brain
injury, including dosing, the age of the animal, and the
timing of replacement. A recent study [72] administering
17β-estradiol to OVX rats that underwent MCAO found that
slow-release commercially purchased pellets of 17β-estradiol
produced an early supraphysiological peaks followed by a
substantial decrease in serum levels of E2, while silastic
capsules (inner/outer diameter: 1.575/3.175mm) yielded
17β-estradiol concentrations within the physiological range
for at least 4 weeks. The former was detrimental and
exacerbated brain injury, whereas the latter was beneﬁcial in
reducing MCAO-induced brain damage. The stroke model
itselfmayalsoexertaninﬂuenceontheeﬀectofE2 treatment.
Although most studies with transient MCAO conﬁrmed the
neuroprotective eﬀect of E2 replacement [63], 17β-estradiol
treatment following permanent MCAO did not improve
stroke outcomes; however commercial pellets were used,
and supraphysiological levels of E2 could account for this
discrepancy [73].
Interestingly, it is becoming increasingly accepted that
the eﬀect of sex on stroke outcome may also be hormone
independent. Innate sex diﬀerences also contribute to the
variability of infarct volumes induced by MCAO in male
and female animals. It is increasingly recognized that dif-
ferent cell death pathways may predominate, respectively,
in male and female subjects exposed to ischemic injury
[74] (Figure 4). Cytochrome C-caspase pathway was found6 Journal of Biomedicine and Biotechnology
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Figure 4: Mechanisms of PARP-AIFand cytochrome C-caspase-mediated cell death pathways predominant, respectively, in male and female
brains after ischemia. The ﬁgure was produced using Servier Medical Art.
to be the predominant cell death pathway in females
after ischemic insults [31, 75]. Administration of broad
spectrum caspase inhibitor, quinoline-Val-Asp(Ome)-CH2-
O-phenoxy(Q-VD-OPh),decreasedinfarctvolumesinOVX
female mice after MCAO but had no eﬀect in males [31].
On the other hand, PARP-1-AIF pathway mediates cell death
induced by ischemic insults mainly in male animals [76, 77].
ThePARP-1inhibitorminocyclineisneuroprotectiveinmale
mice but not in OVX females after MCAO [78], which
awaits conﬁrmation. Aging female mice exhibited larger
infarct volumes than aging males after 24h of 90-minute
MCAO, although the serum levels of E2 were equivalently
low in both aging males and females [41]. Female rats are
more vulnerable to the long-term consequences of neonatal
inﬂammatory injury compared to neonatally injured males
[79].
The sexual dimorphism seen in MCAO in aging ani-
mals may also be due to diﬀering inﬂammatory responses
to stroke in aging males and females. A growing body
of evidence suggests that sexual dimorphism exists in
the inﬂammatory response and even in the frequency of
pro/anti-inﬂammatory gene variants [80]. Leukocyte func-
tion varies by sex in aging rats; aging males are less immune
competent than age-matched females as females showed
higher lymphoproliferative responses, higher Natural Killer
activity, and higher IL-2 release in the spleen and axillary
nodes [81]. In previous studies in aging mice, [41]w ef o u n d
that the serum levels of IL-6, a potent proinﬂammatory
cytokine [82, 83], were lower in aging males than in
aging females after MCAO. Indeed, these sex diﬀerences
can also be recapitulated in neonatal animals [75], where
circulating hormone levels are equivalent [84]. All these
studies suggested that sex is an independent viable that
must be addressed in translational stroke studies if we
hope to develop eﬃcacious neuroprotective agents from our
animal models. Sex diﬀerences in stroke must be considered
as an independent viable when interpreting results from
either experimental or clinical trials for neuroprotective
agents.
In summary, the MCAO model in rodents provides a
useful tool to stroke researchers; nevertheless, timing of
analysis, animal age, and sex are important factors that have
major eﬀects on stroke outcome but continue to be less
studied. We must keepin mind theseinﬂuential factorswhen
designing our experiments and in our attempts to translate
therapies into the clinical populations at the highest risk for
stroke, women and the elderly.
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